Drugs / Autologous adipose derived mesenchymal cells
Autologous adipose derived mesenchymal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02326935 | Nov 2014 → May 2018 | multiple sclerosis | American CryoStem Corporation | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous adipose derived mesenchymal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02326935 ↗ |
| Known as | ADSC | “Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection Other Names: ADSC, mesenchymal...” NCT02326935 ↗ |
| Known as | mesenchymal cells | “Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection Other Names: ADSC, mesenchymal...” NCT02326935 ↗ |
| Known as | stromal cells | “Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection Other Names: ADSC, mesenchymal...” NCT02326935 ↗ |
| Modality | Cell therapy | “cellular infusion therapy” NCT02326935 ↗ |
| Route | Intravenous | “via intravenous injection” NCT02326935 ↗ |